Axillary pathologic complete response (pCR) was associated with improved 10-year overall survival (OS) and relapse-free survival (RFS) in a study of 1,600 women who received a diagnosis of breast cancer stages II to III with cytologically confirmed axillary metastases and who received primary systemic chemotherapy (PST). Researchers found:
• A total of 454 patients (28.4%) achieved axillary pCR.
• Patients with axillary and breast pCR after PST had superior long-term survival outcomes.
• Patients undergoing HER2-targeted therapy for HER2-positive disease had high rates of axillary pCR, and those with axillary pCR had excellent 10-year OS.
Citation: Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. [Published online ahead of print December 30, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.4935.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al